First Trust Advisors LP boosted its holdings in Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 101.5% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 605,454 shares of the biopharmaceutical company’s stock after purchasing an additional 304,999 shares during the quarter. First Trust Advisors LP’s holdings in Intercept Pharmaceuticals were worth $35,371,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in ICPT. IFP Advisors Inc boosted its holdings in Intercept Pharmaceuticals by 90.9% in the third quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,182 shares in the last quarter. Birchview Capital LP acquired a new position in Intercept Pharmaceuticals in the third quarter valued at approximately $250,000. Oppenheimer & Co. Inc. boosted its holdings in Intercept Pharmaceuticals by 145.1% in the third quarter. Oppenheimer & Co. Inc. now owns 4,785 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 2,833 shares in the last quarter. Exane Derivatives boosted its holdings in Intercept Pharmaceuticals by 46,054.5% in the third quarter. Exane Derivatives now owns 5,077 shares of the biopharmaceutical company’s stock valued at $295,000 after purchasing an additional 5,066 shares in the last quarter. Finally, Rothschild Investment Corp IL boosted its holdings in Intercept Pharmaceuticals by 22.0% in the third quarter. Rothschild Investment Corp IL now owns 5,846 shares of the biopharmaceutical company’s stock valued at $339,000 after purchasing an additional 1,054 shares in the last quarter. 78.39% of the stock is owned by hedge funds and other institutional investors.
Shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) opened at $61.16 on Tuesday. Intercept Pharmaceuticals Inc has a 52 week low of $51.05 and a 52 week high of $135.59. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95.
Intercept Pharmaceuticals (NASDAQ:ICPT) last released its quarterly earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($3.39) by ($1.04). Intercept Pharmaceuticals had a negative return on equity of 207.27% and a negative net margin of 275.18%. The company had revenue of $37.69 million for the quarter, compared to analysts’ expectations of $39.01 million. During the same quarter last year, the company earned ($4.84) EPS. Intercept Pharmaceuticals’s revenue for the quarter was up 173.1% compared to the same quarter last year. sell-side analysts anticipate that Intercept Pharmaceuticals Inc will post -13.16 earnings per share for the current fiscal year.
A number of equities research analysts have weighed in on ICPT shares. Oppenheimer reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research note on Monday, January 29th. Wedbush reiterated a “buy” rating and issued a $253.00 price objective on shares of Intercept Pharmaceuticals in a research note on Friday, December 22nd. Citigroup set a $74.00 price objective on Intercept Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, December 21st. ValuEngine cut Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $253.00 price objective (down previously from $332.00) on shares of Intercept Pharmaceuticals in a research note on Thursday, January 25th. Four investment analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the stock. Intercept Pharmaceuticals has an average rating of “Hold” and an average target price of $128.75.
TRADEMARK VIOLATION NOTICE: This article was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another domain, it was copied illegally and republished in violation of international trademark & copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2018/02/20/intercept-pharmaceuticals-inc-icpt-shares-bought-by-first-trust-advisors-lp.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.